MedTrace Logo

Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome

NCT04512443 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2020-08-13

No results posted yet for this study

Summary

The article presents the results of a randomized, placebo-controlled study of the conservative treatment with Daflon (Detralex) in female patients with Pelvic congestion syndrome .

Conditions

  • Pelvic Congestion Syndrome

Interventions

DRUG

Daflon

All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).

Sponsors & Collaborators

  • Interregional Clinical Diagnostic Center, Russia

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-28
Primary Completion
2020-03-28
Completion
2020-03-28

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04512443 on ClinicalTrials.gov